<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172768</url>
  </required_header>
  <id_info>
    <org_study_id>MATADOR</org_study_id>
    <nct_id>NCT02172768</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease</brief_title>
  <acronym>MATADOR</acronym>
  <official_title>Pharmacokinetics of Micafungin (Mycamin ®) as Antifungal Prophylaxis Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is as follows:&#xD;
&#xD;
      To determine the pharmacokinetics of micafungin given twice weekly in patients at risk for&#xD;
      developing an invasive fungal disease (patients who are being treated for acute or chronic&#xD;
      graft versus host disease; patients receiving reduced intensity conditioning for Stem Cell&#xD;
      Transplant (SCT); receiving first remission induction chemotherapy for Acute Myeloid&#xD;
      Leucaemia (AML)/MyeloDysplasticSyndrome (MDS)) compared to the pharmacokinetics of micafungin&#xD;
      given daily.&#xD;
&#xD;
      The secondary objective of this trial is as follows:&#xD;
&#xD;
      To determine whether adequate exposure of micafungin is attained. To determine the safety of&#xD;
      micafungin in this patient population&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Micafungin has been shown to be a reasonable option for treating invasive aspergillosis in&#xD;
      hematopoietic stem cell transplantation (HSCT) recipients and has proven as effective as&#xD;
      fluconazole for prophylaxis. Whilst micafungin has much to offer, little is known about its&#xD;
      pharmacokinetic profile in specific patient populations, specifically concerning alternate&#xD;
      dosing strategies with increased dosages over a prolonged dosing interval. Sufficient data&#xD;
      are lacking up to now for twice weekly administration of micafungin as antifungal&#xD;
      prophylaxis. Decreasing the dosing frequency to twice weekly seems a reasonable approach&#xD;
      considering the long terminal elimination life (i.e. 10-17 h) and considering the data&#xD;
      available from murine models that support the use of less frequent dosing with higher&#xD;
      dosages.&#xD;
&#xD;
      It will enable us to characterize both the pharmacokinetics of micafungin in the hematology&#xD;
      cohort and directly compare the exposure to the alternate dosing strategy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>area under the curve</measure>
    <time_frame>day 4 and day 8</time_frame>
    <description>Full pharmacokinetic curves will be taken op Day 4 or 5 and Day 8 (micafungin). AUC of two dosing regimens will be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>population PK model</measure>
    <time_frame>Day 4 and Day 8</time_frame>
    <description>to perform Monte Carlo simulations to provide the scientific background for alternate dosing strategies in the prophylactic setting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>day 1- 11</time_frame>
    <description>number and severity of adverse events will be recorded during the study and both treatment regimens will be compared</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Acute Graft Versus Host Disease Grade II-IV</condition>
  <condition>Allogeneic Stem Cell Transplant</condition>
  <condition>Acute Myeloid Leucaemia</condition>
  <condition>Myelo Dysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>alternate dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment for 8 days with intravenous micafungin twice weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>daily dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>micafungin daily for 8 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>alternate dosing</intervention_name>
    <description>treatment for 8 days with intravenous micafungin twice weekly</description>
    <arm_group_label>alternate dosing</arm_group_label>
    <other_name>micafungin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>daily dosing</intervention_name>
    <description>micafungin daily for 8 days</description>
    <arm_group_label>daily dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>micafungin</intervention_name>
    <arm_group_label>alternate dosing</arm_group_label>
    <arm_group_label>daily dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient receives immunosuppressive therapy for acute GvHD grade II-IV or reduced&#xD;
             intensity conditioning regimens for allogeneic stem cell transplant, or patients&#xD;
             receiving first remission induction chemotherapy for AML/MDS.&#xD;
&#xD;
          -  Subject is at least 18 of age on the day of providing informed consent.&#xD;
&#xD;
          -  Has no signs or symptoms of invasive fungal disease&#xD;
&#xD;
          -  If a woman, is neither pregnant nor able to become pregnant and is not nursing an&#xD;
             infant.&#xD;
&#xD;
          -  Less than 1 week of immunosuppressive therapy for grade II-IV acute GvHD.&#xD;
&#xD;
          -  Is managed with a central venous catheter (preferably a quadruple Arrow-Howes™&#xD;
             Quad-Lumen 8.5,5 French; Arrow International).&#xD;
&#xD;
          -  Subject is able and willing to sign the Informed Consent before screening evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented history of sensitivity to medicinal products or excipients similar to those&#xD;
             found in the micafungin preparation.&#xD;
&#xD;
          -  History of or current abuse of drugs, alcohol or solvents.&#xD;
&#xD;
          -  Inability to understand the nature of the trial and the procedures required.&#xD;
&#xD;
          -  Has not previously participated in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Brüggemann</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Muilwijk EW, Maertens JA, van der Velden WJFM, Ter Heine R, Colbers A, Burger DM, Andes D, Theunissen K, Blijlevens NMA, Brüggemann RJM. Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis. J Antimicrob Chemother. 2018 Nov 1;73(11):3095-3101. doi: 10.1093/jac/dky324.</citation>
    <PMID>30137340</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>alternate dosing</keyword>
  <keyword>micafungin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Micafungin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

